YD Bio (YDES) Non-Current Deferred Tax Liability (2024)

YD Bio's (YDES) quarterly Non-Current Deferred Tax Liability came in at $1.5 billion in Q4 2024.

YD Bio (YDES) Non-Current Deferred Tax Liability (2024) Analysis & Trends

YD Bio (YDES) has 1 years of Non-Current Deferred Tax Liability data on file, last reported at $1.5 billion in Q4 2024.

On a quarterly basis, Non-Current Deferred Tax Liability changed N/A year-over-year to $1.5 billion in Q4 2024; TTM through Dec 2024 was $1.5 billion, a N/A change from a year earlier, with the FY2024 full-year figure at $1.5 billion, changed N/A from the prior year.
Non-Current Deferred Tax Liability for Q4 2024 stood at $1.5 billion.
Over the last five years, Non-Current Deferred Tax Liability for YDES reached as high as $1.5 billion in Q4 2024 and fell as low as $1.5 billion in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-
10	YD Bio	157.46 Mn	151.45 Mn	-

Download Data

Date	Value
Dec 31, 2024	1.46 Bn
Dec 31, 2024	1.46 Bn